CEO Paolo Pucci went through the most recent presentation. No surprises there, but the general mood in the room was upbeat. There were a few moments of humor when some gadfly in the audience asked why one of the candidates standing for election to the bod owned no Arqule stock. Paolo launched into a successful, albeit slightly frenzied, defense of her qualifications stopping just short of comparing her to M. Curie. Btw, there was a total of 6 shareholders signed in for the meeting.
One question that was asked from the audience: "Assuming ARQ-197 goes on to a phase III what is the timeframe?" Paolo's answer was that if the trial went forward by the end of this year, and it went smoothly, it would be 2014 when the final results are tabulated and analyzed.
Another point he made was how hard the staff had worked to just make the ASCO "late breaking" deadline, and how pleased he was that Arqule was included in the oral presentations.